BioSpace News Archive

The global biologics contract development market was estimated at USD 5.61 billion in 2021 and it is expected to surpass around USD 13.7 billion by 2030, poised to grow at a CAGR of 10.43% from 2022 to 2030

Ichor Life Sciences, a preclinical contract research organization, announced a $1.5 million investment in MitoChem Therapeutics.

Beta Bionics, Inc. — a clinical-stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — announced the appointment of Sean Saint to the role of Chief Executive Officer.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of September.

VBL Therapeutics, a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Athira Pharma, Inc. (NASDAQ: ATHA), today announced the company’s financial results for the second quarter ended June 30, 2022 and reviewed recent clinical and corporate updates.

Icosavax, Inc. (Nasdaq: ICVX), today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine.